SIGA Technologies, Inc.

NASDAQ:SIGA

Drug Manufacturers - Specialty & Generic

Healthcare
$2.80 -0.36%

-$0.02 today

Market cap
$201.19M
Beta
0.85
P/E (TTM)
15.2
EPS (TTM)
$0.28
Dividend yield
13.97%
52W Low $4.10High $9.62

Volume 0.37M

Average 0.61M

SIGA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

SIGA Technologies, Inc.NASDAQ: SIGA

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 52.9%

Gross margin was 52.9% in Q1 FY2026, down 44.9 pp from a year earlier. On a trailing-twelve-month basis it was 65.4%, down 11.2 pp year over year. Over 3 fiscal years it narrowed by 22.0 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
52.9%+31.7 pp QoQ
Last fiscal yearDec 2025
68.6%-8.9 pp YoY
LTMMar 2026
65.4%-11.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-44.9 pp——
1 year-8.9 pp——
3 years-22.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
68.6%
Year-over-year change
-8.9pp

Gross Margin vs competitors

How SIGA compares with its peers on the latest reported figures

  • SIGA's LTM Mar 2026 gross margin of 65.4% is the 4th highest of the 9 companies compared; the peer median is 64.2%.
  • Its year-over-year change of -11.2 pp is the lowest of 9, against a peer median of -0.5 pp.
  • Over three fiscal years its change of -22.0 pp compares with a peer median of +2.9 pp.
SIGA Competitors Peer median
Gross Margin for SIGA and competitors
Company Period LTM level YoY 3-year change
CTMXCytomX Therapeutics, Inc.LTM Mar 202699.3% -0.7 pp+0.0 pp
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202693.4% +3.7 pp-5.2 pp
ORGOOrganogenesis Holdings Inc.LTM Mar 202670.4% -5.4 pp-1.1 pp
SIGASIGA Technologies, Inc.LTM Mar 202665.4% -11.2 pp-22.0 pp
ESPREsperion Therapeutics, Inc.LTM Mar 202665.0% -0.3 pp+3.7 pp
AQSTAquestive Therapeutics, Inc.LTM Mar 202663.5% -4.9 pp+2.1 pp
DRIODarioHealth Corp.LTM Mar 202656.5% -9.7 pp+21.7 pp
EBSEmergent BioSolutions Inc.LTM Mar 202644.4% +8.0 pp+4.9 pp
SNDLSNDL Inc.LTM Mar 202627.2% +0.6 pp+7.6 pp
OLMAOlema Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding SIGA) 64.2%-0.5 pp+2.9 pp

Competitors are the stored peer set for SIGA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue133.67M110.78M139.92M138.72M94.6M
Cost of Revenue16.6M10.43M17.83M31.29M29.7M
Gross Profit117.07M100.34M122.09M107.43M64.87M
Gross Margin87.6%90.6%87.3%77.4%68.6%
Research & Development9.94M22.53M16.43M12.31M6.53M
Selling, General & Admin18.03M35.12M22.04M25.14M3.13M
Operating Expenses27.98M57.64M38.47M37.45M41.17M
Depreciation & Amortization522.37K517.64K538.29K538.42K562.61K
EBITDA89.83M44.65M88.31M76.61M30.96M
EBITDA Margin67.2%40.3%63.1%55.2%32.7%
Operating Income89.09M42.7M83.62M69.98M23.7M
Operating Margin66.7%38.5%59.8%50.4%25.1%
Interest Income00006.68M
Interest Expense00000
Other Income / Expenses218.94K1.43M4.16M6.09M6.7M
Income Before Tax89.31M44.13M87.78M76.07M30.4M
Pre-Tax Margin66.8%39.8%62.7%54.8%32.1%
Income Tax Expense19.86M10.23M19.71M16.86M7.1M
Net Income69.45M33.9M68.07M59.21M23.3M
Net Margin52.0%30.6%48.6%42.7%24.6%
EPS (Basic)0.920.460.950.830.33
EPS (Diluted)0.910.460.950.830.33
Weighted Avg Shares75.32M72.93M71.36M71.25M71.6M
Weighted Avg Shares (Diluted)76.4M73.55M71.68M71.77M71.6M

SIGA Technologies, Inc.

NASDAQ:SIGA

Intrinsic Alpha fair value

Locked

Current Price

$2.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.